Everyone watches the molecule. The industry’s attention flows to trial readouts, approval decisions, and launch-day announcements , the visible milestones of a biotech company’s journey from lab to market. But the factor that quietly determines whether a commercial launch holds together is rarely discussed at all: the planning infrastructure underneath it.
I have spent more than sixteen years in supply chain planning, and I have lived through the clinical-to-commercial transition at more than one biotech organisation. The pattern is remarkably consistent. Demand volumes, distribution complexity, and regulatory obligations expand far faster than the planning systems supporting them , leaving forecasting and inventory decisions dependent on manual, disconnected processes at exactly the moment reliability matters most.
This is not a technology story. It is a story about a structural gap that most companies discover only after it has already cost them.
The Gap Nobody Budgets For
A clinical-stage biotech can survive on spreadsheets. Volumes are small, the product portfolio is narrow, and a handful of planners can hold the whole picture in their heads. Each planner builds their own forecast, in their own file, on their own cadence , and because the organisation is small, the seams rarely show.
Commercial scale breaks every one of those assumptions at once. Suddenly there are market demand signals instead of enrollment curves, distributors and wholesalers instead of trial sites, and a regulatory environment in which a supply interruption is a reportable event rather than an internal inconvenience. The planning workload does not grow linearly with revenue; it grows with the number of nodes, products, markets, and handoffs , which is to say, combinatorially.
Yet planning infrastructure is almost never in the commercial-readiness budget. Companies invest heavily in manufacturing capacity, market access, and field teams, then assume the forecasting and inventory processes that worked in the clinic will stretch to cover the launch. In my experience, they don’t stretch , they tear, quietly at first, and then all at once.
The bottom line: the planning gap is not an edge case. It is the default state of a scaling biotech.
Why Clinical Habits Fail at Commercial Scale
Three shifts make the clinical planning model unworkable after launch.
The demand signal changes character. Clinical demand is protocol-driven , enrolment plans, dosing schedules, site counts. Commercial demand is market-driven: payer decisions, prescriber adoption, wholesaler ordering patterns, and competitive dynamics, none of which follow a protocol. A planner who could once reconcile everything in a workbook now faces a signal too volatile and too multi-sourced for any manual process to keep current.
The cost of error becomes asymmetric. In the clinic, a forecasting miss means an overstock write-off or a scramble to resupply a trial site , painful, but contained. At commercial scale, a shortfall means patients who cannot fill prescriptions, and regulators treat it accordingly. The same forecasting gap that was once an internal inconvenience becomes a matter of patient access, regulatory standing, and market credibility all at once.
Consensus stops being optional. A clinical-stage company can tolerate five planners with five versions of the truth. A commercial company cannot, because manufacturing, finance, and commercial teams are now making capital and contractual commitments against the plan. Without a binding consensus process, every function optimises against its own numbers , and the misalignment compounds as the portfolio grows.
What Closing the Gap Actually Looks Like
I have seen this transition handled well, and the winning pattern has little to do with any particular software vendor. It rests on three moves, in a specific order.
Govern the process before you automate it. The organisations that succeed start by replacing individual, ad-hoc forecasting with a governed consensus process: one cadence, one set of roles, one binding demand plan that every function signs. In my experience implementing planning platforms at scaling biotechs, the discipline of a standardised monthly cycle , where discrete products with different timelines are brought into a single rhythm , delivered as much value as any system feature. A tool that automates an ungoverned process simply produces disagreement faster.
Integrate end to end, or don’t bother. The distinguishing feature of commercial-grade planning infrastructure is not sophistication; it is connectedness. Demand, supply, inventory, and production planning must operate from a single source of truth, with data flowing automatically from source systems rather than being re-keyed into spreadsheets. When these functions were connected on a unified platform in one transition I supported, the organisation eliminated an enormous amount of manual data assembly work , and forecast accuracy became measurable for the first time, because there was finally one forecast to measure.
Treat change management as half the project. Planning infrastructure fails socially before it fails technically. Planners who have spent years trusting their own workbooks will quietly keep them unless training, hypercare support, and visible governance make the new process the path of least resistance. The go-live is not the finish line; adoption is.
Infrastructure as a Prerequisite, Not a Follow-On
Here is the reframe that separates the organisations that scale smoothly from those that stumble: planning infrastructure is a component of commercial readiness, not a post-launch optimisation project.
Commercial readiness planning typically covers manufacturing, distribution networks, and quality systems. Planning infrastructure belongs on that list, and for a reason the clinical stage obscures: supply interruptions at commercial scale carry consequences that clinical-stage shortfalls simply don’t. A stockout is a patient harmed, a regulatory posture weakened, and a market position surrendered to a competitor , often simultaneously.
The sequencing matters because planning infrastructure cannot be stood up reactively. A governed consensus process takes months of design, testing, and adoption work before it produces a trustworthy plan. A company that waits for its first commercial forecasting crisis to invest has, by definition, already paid the cost the investment was meant to prevent.
There is also a compounding argument. The first product launch is the cheapest moment a company will ever have to build integrated planning, because every subsequent launch inherits the foundation. Organisations that defer the work don’t just carry risk on product one; they rebuild fragmented processes on every product that follows.
The Quiet Determinant
The biotech industry has become exceptionally good at the science of scaling , process development, tech transfer, capacity expansion. The management infrastructure of scaling has not kept pace, and planning is where the lag shows first.
The companies that navigate the clinical-to-commercial transition well are not the ones with the most sophisticated tools. They are the ones that recognised, early, that a forecast at commercial scale is a commitment , to patients, to regulators, and to the market , and built the governed, integrated infrastructure that makes such a commitment keepable.
The molecule gets you approved. The planning infrastructure keeps you on the market.
